FIELD: medicine.
SUBSTANCE: set of inventions relates to medicine and concerns a stable liquid pharmaceutical composition containing 10 to 150 mg/ml of antibody against IL-1beta which is in the form of ACZ885, where the buffer system is in the form of histidine in a concentration of 10 to 50 mM, stabilizer is selected from a group consisting of mannite, sorbit and trehalose and pH of formulation ranges from 5.5 to 7.5. Set of inventions also concerns syringe containing above-mentioned liquid composition and automotive injector containing the above-mentioned liquid composition.
EFFECT: set of inventions ensures the preservation of at least 70% of the activity of the composition after storage for a period of 24 months at 25°C, as determined by analysis using a reporter gene.
13 cl, 1 ex, 2 dwg, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-CONTAINING COMPOSITIONS | 2009 |
|
RU2563179C2 |
| NOVEL APPLICATION OF IL-1β COMPOUNDS | 2012 |
|
RU2571563C2 |
| NEW APPLICATION OF IL-1β COMPOUNDS | 2006 |
|
RU2468817C2 |
| NEW INDICATIONS FOR USE IN TREATING ANTIBODIES AGAINST IL-1-BETA | 2014 |
|
RU2698208C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| NEW STABLE COMPOSITIONS FOR FXIA ANTIBODIES | 2018 |
|
RU2775692C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| LIQUID COMPOSITION CONTAINING ANTIBODY TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | 2020 |
|
RU2814172C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
